-+ 0.00%
-+ 0.00%
-+ 0.00%

GALMED ANNOUNCES THE BREAKTHROUGH DEVELOPMENT OF NOVEL LNP CARDIAC TARGETED FORMULATION OF ITS SCD1 INHIBITOR, ARAMCHOL

Reuters·07/16/2026 11:30:10

Please log in to view news